The FDA issued updates on September 12 regarding drugs that are currently in shortage:
- Cefotetan Disodium Injection (Updated – Currently in Shortage)
- Imipenem and Cilastatin for Injection, USP (Updated – Currently in Shortage)
- Leucovorin Calcium Lyophilized Powder for Injection (Updated – Currently in Shortage)
- Lidocaine Hydrochloride (Xylocaine) Injection (Updated – Currently in Shortage)
- Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine (Updated – Currently in Shortage)
- Methylprednisolone Sodium Succinate for Injection, USP (Updated – Currently in Shortage)
- Multi-Vitamin Infusion (Adult and Pediatric) (Updated – Currently in Shortage)
- Multi-Vitamin Infusion (Adult and Pediatric) (Updated – Discontinuation)
- Potassium Chloride Injection (Updated – Currently in Shortage)
- Potassium Phosphate Injection (Updated – Currently in Shortage)
- Rocuronium Bromide Injection (Updated – Currently in Shortage)
- Sodium Acetate Injection, USP (Updated – Currently in Shortage)
- Sodium Bicarbonate Injection, USP (Updated – Currently in Shortage)
- Montelukast Sodium Chewable Tablet (New – Discontinuation)
According to the FDA:
“A drug receives Resolved status when the Drug Shortages Staff (DSS) determines that the market is covered, based on information from all manufacturers. The market is considered covered when supply is available from at least one manufacturer to cover total market demand. However, some manufacturers may not have all presentations available. DSS monitors the supply of products with Resolved status. For the most current supply information, contact the manufacturers.”
(Source: U.S. Food & Drug Adminstration)
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
